AI Terminal
Fresenius Medical Care AG & Co. KGaA
Transaction in Own Shares • Feb 20, 2019
165_rns_2019-02-20_dcc3231e-09c9-4247-ab74-5382930b55af.html
Transaction in Own Shares
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 20 February 2019 07:01
Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care resolves share repurchase program with an aggregate volume of up to one billion Euros
Fresenius Medical Care AG & Co. KGaA / Key word(s): Share Buyback
Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care resolves share repurchase program with an aggregate volume of up to one billion Euros
20-Feb-2019 / 07:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has resolved to repurchase shares of the Company with an aggregate volume of up to one billion Euros via the capital markets over the next two years.
The share repurchase program will be carried out in several tranches and in accordance with the EU safe harbor provisions. Further details will be disclosed prior to the start of the share repurchase program.
Person making the notification:
Dr. Dominik Heger
SVP Investor Relations & Corporate Communications
Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,928 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 333,331 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company’s website at www.freseniusmedicalcare.com.
Contact:
Dr. Dominik Heger
SVP & Head of Investor Relations & Corporate Communications
P. +49 6172 609 2601
20-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Fresenius Medical Care AG & Co. KGaA |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg | |
| Germany | |
| Phone: | +49 (0) 6172- 609 2525 |
| Fax: | +49 (0) 6172- 609 2301 |
| E-mail: | [email protected] |
| Internet: | www.freseniusmedicalcare.com |
| ISIN: | DE0005785802 |
| WKN: | 578580 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange |
| End of Announcement | DGAP News Service |